Adult ADHD is no longer an afterthought in psychiatry—but its treatment options have remained surprisingly narrow. While stimulant medications remain highly effective for many, a significant proportion of adults either cannot tolerate them, prefer non-pharmacological approaches, or need additional tools to manage attentional difficulties in daily life.

This is where Prismira, also known as LumosityRX, marks an important shift.

Prismira is an FDA-cleared prescription digital therapeutic indicated to improve attention function in adults aged 22–55 years with primarily inattentive or combined-type ADHD. It represents a new category of treatment—neither medication nor traditional psychotherapy, but a rigorously tested, software-based intervention grounded in cognitive neuroscience.

Why Adult ADHD Needed New Treatment Options

Adult ADHD often looks different from childhood ADHD. Hyperactivity may fade, but inattention persists—manifesting as:

• Difficulty sustaining focus at work

• Mental fatigue and task switching

• Reduced productivity despite effort

• Emotional strain from constant self-monitoring

In real-world clinical practice, many adults benefit from a layered approach: medication plus skills, structure, and cognitive support. Prismira was developed to address a core mechanism underlying ADHD—attention regulation itself.

From Lumosity to LumosityRX: When Cognitive Science Becomes Clinical

Prismira builds on the scientific foundation of Lumosity, a platform used worldwide for cognitive training in healthy individuals. Over nearly two decades, Lumosity scientists and academic collaborators have published more than 130 peer-reviewed studies examining attention, learning, and neuroplasticity.

The crucial step was not rebranding—but re-engineering.

For Prismira, researchers selected 13 Lumosity games most relevant to attentional control and embedded them within a structured, adaptive therapeutic program. The result is a guided intervention, typically used for about 15 minutes per day, with personalization, feedback, and progress tracking—designed for adults with ADHD, not casual users.

The Evidence Behind FDA Clearance

Prismira’s FDA clearance is based on a large randomized controlled trial, the gold standard of clinical research.

• 560 adults with ADHD

• 13 independent clinical sites

• 9-week intervention period

• Conducted between May 2022 and March 2024

Participants using Prismira demonstrated statistically significant improvement in attention compared to a control group, measured using the Test of Variables of Attention (TOVA)—a validated measure of sustained and selective attention.

Additional findings included:

• Clinician-rated global improvement on the CGI-I scale

• Meaningful improvements in quality of life, including emotional balance and productivity

• Excellent safety profile, with no serious adverse events

These results were reviewed by the U.S. Food and Drug Administration, leading to FDA clearance under the name Prismira.

What Prismira Treats—and What It Does Not

It’s important to be precise.

Prismira is indicated to improve attention function, as measured digitally. Patients may not necessarily show improvement in all behavioral symptoms, such as hyperactivity or impulsivity. This makes Prismira best understood as a mechanism-targeted intervention, rather than a comprehensive standalone treatment.

Prismira should be considered as part of a broader therapeutic program, which may include:

• Clinician-directed psychotherapy

• Medication, when appropriate

• Psychoeducation and skills training

Limitations include unsuitability for individuals with photosensitive epilepsy, certain visual impairments (such as color blindness), or physical limitations affecting mobile device use.

Why Prismira Matters for the Future of ADHD Care

Prismira signals a quiet but important evolution in psychiatry. Treatment is moving beyond a medication-only model toward precision, mechanism-based care, where interventions directly engage the cognitive systems they aim to improve.

Digital therapeutics like Prismira are not wellness apps. They are evidence-bound clinical tools, required to demonstrate benefit, safety, and appropriate use. When used thoughtfully, they expand—not replace—the clinician’s toolkit.

For adults with inattentive or combined-type ADHD, this represents a meaningful new option: structured, engaging, safe, and scientifically validated.

Self-Promotion / Clinical Perspective

Dr. Srinivas Rajkumar T, MD (AIIMS), DNB, MBA (BITS Pilani)
Consultant Psychiatrist & Neurofeedback Specialist
Mind & Memory Clinic, Apollo Clinic Velachery (Opp. Phoenix Mall)

In my clinical practice, I strongly advocate multimodal, evidence-based ADHD care—combining careful clinical assessment, judicious medication use, cognitive training, neurofeedback, and psychoeducation. FDA-cleared digital therapeutics like Prismira reflect the direction modern psychiatry is heading: precise, personalized, and grounded in neuroscience rather than assumptions.

If you are an adult struggling with inattention, productivity issues, or executive dysfunction—and are exploring structured, non-pharmacological or adjunctive options—an individualized evaluation is essential to determine what combination of approaches will work best for you.

✉ srinivasaiims@gmail.com
📞 +91-8595155808

This article is for educational purposes only and does not replace professional medical advice or consultation.